The Synucleinopathies: Twenty Years On.
The Synucleinopathies: Twenty Years On.
复制标题
DOI：
10.3233/jpd-179005
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Spillantini MG
中科院分区：
文献类型：
--
作者：
Goedert M;Jakes R;Spillantini MG
到2017年，距离詹姆斯·帕金森首次对以他的名字命名的疾病进行完整的临床描述已有200年，距离高剂量D，L-DOPA治疗的引入已有50年，距离α-突触核蛋白聚集出现已有20年。1998年，多系统萎缩与帕金森病和路易体痴呆一起成为第三大突触核蛋白病。在这里，我们回顾了我们的工作，这导致了路易体，路易神经突和Papp-Lantos体中α-突触核蛋白的鉴定，以及此后发生的事情。所描述的一些实验是与ML施密特、VMY Lee和JQ Trojanowski合作进行的。
In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since α-synuclein aggregation came to the fore. In 1998, multiple system atrophy joined Parkinson’s disease and dementia with Lewy bodies as the third major synucleinopathy. Here we review our work, which led to the identification of α-synuclein in Lewy bodies, Lewy neurites and Papp-Lantos bodies, as well as what has happened since. Some of the experiments described were carried out in collaboration with ML Schmidt, VMY Lee and JQ Trojanowski.